ClinicalTrials.gg
Active, not recruitingNCT04522076TARGET-VIPUpdated May 30, 2025

Prospective Hospital Registry of Patients With Suspected or Confirmed Coronavirus Infection (COVID-19) and Community-acquired Pneumonia

An observational study in COVID 19, sponsored by National Research Center for Preventive Medicine. Active, not recruiting at 2 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-30.

Sponsored by National Research Center for Preventive Medicine · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,130
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 144 studies in COVID-19 with a site in Russian Federation — 4 open to participants now, 9 under way, 1 of them phase 3. COVID-19 · Russian Federation.

Enrollment
10th of 39
1,130 · median 220
Started
2020
with 85 others
Observational
39 of 144
3 open now
Registered
37th of 144
by date

Among the 144 studies in COVID-19 with a site in Russian Federation, this one is the 10th largest by enrollment of the 39 observational ones that give a count, is one of 86 that started in 2020, is one of 39 observational ones, and was the 37th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 144 studies in COVID-19 with a site in Russian Federation are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in COVID-19 with a site in Russian Federation, or all of them as a file.
02

Study summary

Coronavirus-2019 disease (COVID-19) and community-acquired pneumonia are significant problems of modern medicine. Pneumonia is the most common severe complication of COVID-19. But at the same time, COVID-19 is not the only cause of community-acquired pneumonia. Moreover, pneumonia is only one of the numerous possible severe complications of COVID-19. Medical centers specialized for the hospital treatment of patients with severe COVID-19 and community-acquired pneumonia were organized in different regions of Russia during coronavirus pandemic-2020. The indications for hospitalization to one of these centers based in the National Medical and Surgical Center (NMSC) are: confirmed or suspected severe COVID-19 or community-acquired pneumonia.

A prospective medical registry of such patients hospitalized to NMSC, is intended to analyze and compare their clinical and instrumental data, co-morbidity, treatment, short-term and long-term outcomes in real clinical practice.

Stage 1. Hospital treatment in NMSC

Duration of this stage: from the date of admission to the hospital up to the date of discharge from the hospital / or up to the date of death during the reference hospitalization. The date of admission to the hospital will be the date of enrollment to the study.

Evaluation of electronic health record data using the Medical Information System (MIS). Assessment of the outcomes of the hospital phase (discharge from the hospital, death) and significant events (acute respiratory and pulmonary failure, requiring mechanical ventilation; cardiovascular events - myocardial infarction, cerebral stroke, acute heart failure, paroxysmal heart rhythm disturbances, bleedings, thrombosis of large vessels and thromboembolic complications). A survey of patients to clarify data on risk factors, somatic diseases, and drug therapy before hospitalization.

COVID-19 was diagnosed when severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was confirmed by Polymerase chain reaction (PCR). Pneumonia was confirmed according to computerized tomography (CT) data.

Stage 2. Prospective outpatient follow-up for 24 months

Duration of this stage: 24 months after discharge from the hospital This work will be delivered by investigators from the National Medical Research Center for Therapy and Preventive Medicine.

Evaluation of long-term outcomes and events among residents of Moscow and the Moscow Region according to a patient survey (contact by phone for 30-60 days, 6 months, 12 and 24 months after discharge from the hospital) and medical records.

03

Conditions studied

  • COVID 19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

From April 6, 2020 until the end of the work period of departments of NMSC, that are specialized for the treatment of patients with COVID-19 and community-acquired pneumonia all patients with inclusion criteria and who don't have exclusion criteria will be included in the study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients hospitalized to the National Medical and Surgical Center named after N.I.Pirogov of the Ministry of Health of Russia (NMSC) with suspected or confirmed COVID-19 or community-acquired pneumonia.
  2. Age 18 years and older.
  3. Permanent residency in Russia.

Exclusion criteria

Exclusion Criteria:

  1. Permanent residency outside of Russia.
  2. The patient's refusal to participate in the study.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,130 participants (actual)
Patient registry
No

Groups and cohorts

  • COVID-19 with pneumonia

    patients with positive COVID 19 by PCR and pneumonia by CT

  • COVID-19 without pneumonia

    patients with positive COVID 19 by PCR and absent of pneumonia by CT

  • Patients with pneumonia and without COVID 19

    patients with negative COVID 19 by PCR and with pneumonia by CT

  • Patients without pneumonia and COVID 19

    Patients with suspected COVID-19 and/or pneumonia at the pre-hospital stage that were not confirmed in hospital

06

What researchers measure

Primary outcomes

  1. Overall survival

    Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days

  2. Time to all-cause mortality or Artificial Pulmonary Ventilation (APV)

    Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days

  3. Time to all-cause mortality, nonfatal myocardial infarction, nonfatal cerebral stroke, and coronary or carotid revascularization

    Time frame: from discharge up to two years after reference hospitalization

Secondary outcomes

  1. Proportion of patients with severe pneumonia

    Damage area \>50% according to the computer tomography data at any time point during hospitalization

    Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days

  2. Proportion of patients with low oxygen saturation value

    SpO2 \<90% - at any point during hospitalization

    Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days

  3. Proportion of patients with Hb <90 g/l (9.0 g/dl) at any point during hospitalization

    Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days

  4. Proportion of patients hospitalized or transferred to Intensive Care Unit (ICU)

    Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days

  5. Overall survival

    Time frame: from discharge up to two years after reference hospitalization

  6. Time to nonfatal myocardial infarction, nonfatal cerebral stroke, and coronary or carotid revascularization

    Time frame: from discharge up to two years after reference hospitalization

  7. Time to pneumonia/recurrent pneumonia

    In patients with pneumonia during reference hospitalization time to recurrent pneumonia. In patients without pneumonia during reference hospitalization - time to first pneumonia

    Time frame: from discharge up to two years after reference hospitalization

  8. Time to primary or recurrent coronavirus infection disease (COVID-19)

    In patients without COVID-19 - time to primary diagnosis and in patients with COVID-19 - time to recurrent event

    Time frame: from discharge up to two years after reference hospitalization

Other outcomes

  1. proportion of patients with nonfatal myocardial infarction

    Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days

  2. proportion of patients with nonfatal cerebral stroke

    Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days

  3. proportion of patients with bleedings

    Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days

  4. thromboembolic events

    proportion of patients with thromboembolic events

    Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days

  5. Duration of Artificial Pulmonary Ventilation

    the sum of the days when the patients required artificial pulmonary ventilation

    Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days

  6. Minimal value of oxygen blood saturation (SpO2) during the hospital stage.

    Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days

  7. Minimal value of hemoglobin (Hb) during the hospital stage

    Time frame: from admission to discharge or death during reference hospitalization, assessed up to 90 days

  8. Rehospitalization due to pneumonia, COVID-19, flu and other acute respiratory infections (ARV)

    proportion of patients with rehospitalization due to pneumonia, COVID-19, flu and other acute respiratory infections (ARV)

    Time frame: from discharge up to two years after reference hospitalization

  9. Hospitalization due to cardiovascular disease (CVD)

    proportion of patients with hospitalization due to cardiovascular disease

    Time frame: from discharge up to two years after reference hospitalization

  10. time to Flu and other ARV (except COVID-19)

    Time frame: from discharge up to two years after reference hospitalization

07

Study locations

2 sites
  • National Research Center for Preventive Medicine of the Ministry of Health
    Moscow, 101990, Russian Federation
  • National Medical and Surgical Center named after N.I.Pirogov of the Ministry of Health of Russian Federation
    Moscow, 105203, Russian Federation
08

References and documents

Publications

  • Drapkina O. M., Karpov O. E., Lukyanov M. M., Martsevich S. Yu., Pulin A. A., Kutishenko N. P., Akimkin V. G., Andreenko E. Yu., Voronina V. P., Dindikova V. A., Dmitrieva N. A., Zagrebelnyi A. V., Ler- man O. V., Makoveeva A. N., Okshina E. Yu., Kudryashov E. V., Klyashtorny V. G., Smirnov A. A., Fomina V. S. Prospective in-hospital registry of patients with suspected or documented COVID-19 infection and community acquired pneumonia (TARGET-VIP): characteristics of patients and assessment of in-hospital outcomes. Cardiovascular Therapy and Prevention. 2020;19(6):2727. (In Russ.) doi:10.15829/1728-8800-2020-2727
  • Drapkina OM, Karpov OE, Loukyanov MM, Martsevich SYu, Pulin AA, Kutishenko NP, Akimkin VG, Andreenko EYu, Voronina VP, Dindikova VA, Dmitrieva NA, Zagrebelnyy AV, Lerman OV, Makoveeva AN, Okshina EYu, Kudryashov EV, Klyashtorniy VG, Smirnov AA, Fomina VS. Experience of creating and the first results of the prospective hospital registry of patients with suspected or confirmed coronavivirus infection (COVID-19) and community-acquired pneumonia (TARGET-VIP). The Russian Journal of Preventive Medicine. 2020;23(8):6- 13. (In Russ.). https://doi.org/10.17116/profmed2020230816
  • Lukyanov M.M., Martsevich S.Yu., Pulin A.A., Kutishenko N.P., Andreenko E.Yu., Voronina V.P., Dindikova V.A., Dmitrieva N.A., Zagrebelny A.V., Makoveeva A.N., Lerman O.V., Okshina E.Yu., Sgibneva A. S., Smirnov A. A., Belova E. N., Klyashtorny V. G., Kudryashov E.V., Karpov O.E., Drapkina O.M. Dynamics of age characteristics and prevalence of concomitant cardiovascular and non-сardiovascular diseases in patients hospitalized with COVID-19 during epidemic wave: data from TARGET-VIP registry. Cardiovascular Therapy and Prevention. 2021;20(8):3106. (In Russ.) doi:10.15829/1728-8800-20213106
  • : Martsevich S.Yu., Lukyanov M.M., Pulin A.A., Kutishenko N.P., Andreenko E.Yu., Voronina V.P., Dindikova V.A., Dmitrieva N.A., Zagrebelnyy A.V., Lerman O.V., Makoveeva A.N., Okshina E.Yu., Smirnov A.A., Kudryashov E.V., Budaeva I.V., Nikoshnova E.S., Karpov O.E., Drapkina O.M. Prehospital Period in Patients with COVID-19: Cardiovascular Comorbidity and Pharmacotherapy During the First Epidemic Wave (Hospital Registry Data). Rational Pharmacotherapy in Cardiology 2021;17(6):873-879. DOI:10.20996/1819-6446-2021-12-13
  • Lukyanov M.M., Kutishenko N.P., Martsevich S.Yu., Pulin A.A., And - reenko E. Yu., Voronina V.P., Dindikova V.A., Dmitrieva N.A., Lerman O.V., Makove - eva A.N., Okshina E.Yu., Sgibneva A.S., Smirnov A.A., Belova E.N., Klyashtorny V.G.,Kudryashov E.V., Karpov O.E., Drapkina O.M. Long-term outcomes in patients after COVID-19: data from the TARGET-VIP registry. Russian Journal of Cardiology. 2022;27(3):4912. doi:10.15829/1560-4071-2022-4912
  • Smirnov A.A., Loukianov M.M., Martsevich S.Yu., Pulin A.A., Kutishenko N.P., Andreenko E.Yu., Voronina V.P., Dindikova V.A., Dmitrieva N.A., Kudryavtseva M.M., Lerman O.V., Makoveeva A.N., Okshina E.Yu., Maltseva A.A., Belova E.N., Klyashtorniy V.G., Kudryashov E.V., Karpov O.E., Drapkina O.M. Clinical and Anamnestic Characteristics, Cardiovascular Pharmacotherapy and Long-term Outcomes in Multimorbid Patients after COVID-19. Rational Pharmacotherapy in Cardiology 2022;18(5):502-509. DOI:10.20996/1819-6446-2022-09-06
  • Loukyanov MM, Andreenko EYu, Martsevich SYu, Kutishenko NP, Voronina VP, Dindikova VA, Dmitrieva NA, Kudryavtseva MM, Lerman OV, Makoveeva AN, Okshina EYu, Smirnov AA, Belova EN, Kudryashov EV, Litinskaya OA, Dzodzuashvili LR, Karpov OE, Pulin AA, Drapkina OM. Long-term follow-up of patients after COVID-19: adherence to SARS-CoV-2 vaccination and immune status. Profilakticheskaya Meditsina. 2022;25(12):88-95. (In Russ.). https://doi.org/10.17116/profmed20222512188
  • Kutishenko N.P., Lukyanov M.M., Martsevich S.Yu., Pulin A.A., Andreenko E.Yu., Voronina V.P., Dindikova V.A., Dmitrieva N.A., Kudryavtseva M.M., Lerman O.V., Makoveeva A.N., Okshina E.Yu., Smirnov А.А., Belova E.N., Klyashtorny V.G., Kudryashov E.V., Karpov O.E., Drapkina O.M. Medical treatment of patients with cardiovascular diseases during the first year after hospitalization for COVID-19. Cardiovascular Therapy and Prevention. 2022;21(12):3467. (In Russ.) https://doi.org/10.15829/1728-8800-2022-3467
  • Mareev Yu.V., Lukyanov M.M., Martsevich S.Yu., Pulin A.A., Kutishenko N.P., Andreenko E.Yu., Voronina V.P., Dindikova V.A., Dmitrieva N.A., Makoveeva A.N., Lerman O.V., Okshina E.Yu., Smirnov A.A., Kudryavtseva M.M., Belova E.N., Klyashtorny V.G., Kudryashov E.V., Karpov O.E., Drapkina O.M. Detection rate and characteristics of heart failure, depending on the diagnostic criteria in COVID-19 survivors one year after hospitalization. Cardiovascular Therapy and Prevention. 2022;21(12):3437. (In Russ.) https://doi.org/10.15829/1728-8800-2022-3437
  • Lukyanov M.M., Andreenko E. Yu., Martsevich S. Yu., Kutishenko N.P., Voronina V.P., Dindikova V.A., Dmitrieva N.A., Kudryavtseva M.M., Lerman O.V., Makoveeva A.N., Okshina E. Yu., Pulin A.A., Smirnov A.A., Klyashtorny V.G., Karpov O.E., Drapkina O.M. Two-year outcomes in patients after hospitalization for COVID-19: data from the TARGET-VIP registry. Cardiovascular Therapy and Prevention. 2023;22(10):3757. doi:10.15829/1728-8800-2023-3757
  • Smirnov AA, Loukianov MM, Martsevich SYu, Kutishenko NP, Andreenko EYu, Voronina VP, Dindikova VA, Dmitrieva NA, Kudryavtseva MM, Lerman OV, Makoveeva AN, Okshina EYu, Smirnova MI, Pulin AA, Karpov OE, Drapkina OM. Long-term outcomes in patients with cardiovascular multimorbidity suffered from COVID-19: two-year observation. The Russian Journal of Preventive Medicine. 2023;26(12):58-64. (In Russ.). https://doi.org/10.17116/profmed20232612158
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2020 (actual). Primary completion is estimated for Dec 2026, 80 months after the start.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 80 months is above that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2020
First posted
Aug 21, 2020
StartActual
Apr 6, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04522076
Lead sponsor
National Research Center for Preventive Medicine
Collaborators
National Medical and Surgical Center named after N.I. Pirogov of the Ministry of Healthcare of the Russian Federation
Responsible party
Sponsor
First posted
Aug 21, 2020
Start date
Apr 6, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 30, 2025

Study contacts

Sergey Martsevich, MD, PhD
study chair · National Medical Research Center for Therapy and Preventive Medicine
Mikhail Loukianov, MD, PhD
study chair · National Medical Research Center for Therapy and Preventive Medicine
Andrey Pulin, MD, PhD
study chair · National Medical and Surgical Center named after N.I.Pirogov

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion